|
| 37890124 | Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited. | J Clin Oncol | 2024 |
| 37756364 | Differences in the Course of CD4 and CD8 Cells After Chemoradiotherapy in People Living with HIV with Anal Cancer. | AIDS Res Hum Retroviruses | 2024 |
| 36572280 | Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials. | Radiother Oncol | 2023 |
| 38024242 | Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma. | Neurooncol Adv | 2023 |
| 37720254 | Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea. | Clin Transl Radiat Oncol | 2023 |
| 37625428 | Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right? | Lancet Gastroenterol Hepatol | 2023 |
| 37902752 | Overall Survival After Treatment Failure Among Patients With Rectal Cancer. | JAMA Netw Open | 2023 |
| 37827064 | Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. | Eur J Cancer | 2023 |
| 37429948 | [Preoperative treatment of rectal cancer-Critical comments on the US-American PROSPECT trial]. | Strahlenther Onkol | 2023 |
| 36463667 | Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. | Cancer Treat Rev | 2023 |
| 34838891 | The radiotherapy quality assurance gap among phase III cancer clinical trials. | Radiother Oncol | 2022 |
| 35351796 | Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. | Neurology | 2022 |
| 35395434 | Compliance to chemoradiation in squamous cell carcinoma of the anus. | Cancer Treat Rev | 2022 |
| 35593177 | Advances in nanotechnology-based platforms for survivin-targeted drug discovery. | Expert Opin Drug Discov | 2022 |
| 35449546 | ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. | Clin Transl Radiat Oncol | 2022 |
| 35357413 | Do We Have Enough Evidence to Propose a Preferred Total Neoadjuvant Therapy Sequence for Patients With Locally Advanced Rectal Cancer?-Reply. | JAMA Oncol | 2022 |
| 35445815 | Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. | Strahlenther Onkol | 2022 |
| 36428594 | Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy. | Cancers (Basel) | 2022 |
| 36481692 | Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center. | Sci Rep | 2022 |
| 36139585 | Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial. | Cancers (Basel) | 2022 |
| 36206161 | Image-guided radiotherapy in an orthotopic mouse model of rectal cancer. | STAR Protoc | 2022 |
| 35864412 | Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis. | J Neurooncol | 2022 |
| 35954320 | Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. | Cancers (Basel) | 2022 |
| 35951038 | [Monotherapy with immune checkpoint blockade leads to clinical complete remission in patients with rectal cancer and microsatellite instability]. | Strahlenther Onkol | 2022 |
| 35254485 | Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. | Eur Radiol | 2022 |
| 35120600 | Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. | Cancer Cell | 2022 |
| 34999135 | Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). | Radiother Oncol | 2022 |
| 35327399 | C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. | Biomedicines | 2022 |
| 35166870 | [Radiotherapy dose escalation does not improve local control in patients with esophageal cancer after definitive radiochemotherapy: the ARTDECO randomized phase III trial]. | Strahlenther Onkol | 2022 |
| 35105690 | Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis. | Cancer Res | 2022 |
| 34618171 | Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients. | Strahlenther Onkol | 2022 |
| 34792531 | Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. | JAMA Oncol | 2022 |
| 33383348 | Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. | Eur J Cancer | 2021 |
| 33549260 | Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials. | Mayo Clin Proc | 2021 |
| 33765184 | [Short-term radiotherapy with 5⿯ÿ⿿5⿯Gy followed by preoperative chemotherapy and resection in patients with locally advanced rectal carcinoma results in improved disease-free survival]. | Strahlenther Onkol | 2021 |
| 33596839 | Single-shot bevacizumab for cerebral radiation injury. | BMC Neurol | 2021 |
| 33538917 | A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. | J Cancer Res Clin Oncol | 2021 |
| 33557398 | Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer-A Promising Signaling Network for Therapeutic Interventions. | Cancers (Basel) | 2021 |
| 34731288 | Correction to: Innovative radiation oncology Together-Precise, Personalized, Human. | Strahlenther Onkol | 2021 |
| 34515820 | Innovative radiation oncology Together - Precise, Personalized, Human : Vision 2030 for radiotherapy & radiation oncology in Germany. | Strahlenther Onkol | 2021 |
| 34830902 | Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. | Cancers (Basel) | 2021 |
| 34619239 | Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. | Radiother Oncol | 2021 |
| 34349247 | International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. | Nat Rev Clin Oncol | 2021 |
| 33408118 | A Spatial and Functional Interaction of a Heterotetramer Survivin-DNA-PKcs Complex in DNA Damage Response. | Cancer Res | 2021 |
| 33472203 | Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas. | Oncology | 2021 |
| 32450863 | Management of anal cancer patients - a pattern of care analysis in German-speaking countries. | Radiat Oncol | 2020 |
| 31804659 | Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. | JAMA Oncol | 2020 |
| 33261052 | Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. | Cancers (Basel) | 2020 |
| 32903529 | Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma. | Front Oncol | 2020 |
| 32702645 | Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. | Eur J Cancer | 2020 |